This content is from: Premium Hedge Funds Are Holding Their Breath on This Biopharma IPO Several prominent hedge funds disclosed sizable stakes in PepGen, which went public earlier this month. By Stephen Taub May 23, 2022
This content is from: Portfolio New Valuation Data Show Private Companies Weathering the Downturn Better Than Public Peers Good and bad companies are being treated the same right now. Being able to discern between the two is where the opportunities are, says EQUIAM’s Ziad Makkawi. By Hannah Zhang May 19, 2022
This content is from: Premium Tesla Attracts Major Hedge Funds Several prominent firms established large stakes in the electric vehicle maker in the first quarter. By Stephen Taub May 18, 2022
This content is from: Premium Tiger Global Changes Up Its Private Market Strategy One of the most active venture capital investors is now emphasizing earlier-stage companies. By Stephen Taub March 14, 2022
This content is from: Premium Two Sigma, Renaissance Rebound in 2021 Risk premia and equity quant strategies are solidly in the black this year. By Stephen Taub December 21, 2021
